Tocilizumab, a specific monoclonal antibody that blocks IL-6, has been recommended for use in critically ill COVID-19 patients with extensive bilateral pulmonary lesions and with elevated serum levels of IL-6. The gene discussed is IL6; the disease is COVID-19.